FTSE 100 news / Companies and sectors / AstraZeneca / 30 September 2026
AstraZeneca (AZN): news on Wednesday 30 September 2026
+3.3 positive
Coverage was dominated by AstraZeneca's $2 billion equity investment in Summit Therapeutics, which was widely seen as a strategic oncology move and drew supportive analyst comment. The tone is tempered by reports of the shares slipping on the day.
What drove it
- Summit $2B investment
- oncology pipeline
- share price dip
The 35 stories
- +7.5 AstraZeneca's $2 Billion Investment in Summit Therapeutics Seen as 'Win-Win,' UBS Says
UBS calls the investment win-win. - +6.7 Hutchmed, AstraZeneca Submit Lung Cancer Drug Application for ORPATHYS-TAGRISSO Combination to U.S. FDA
US FDA application submitted for lung cancer combination. - +6.7 Bernstein Maintains AstraZeneca(AZN.US) With Buy Rating, Maintains Target Price $267.63
Bernstein maintains Buy rating. - +5.8 AstraZeneca boards the PD-1/VEGF ship with $2B Summit investment
AstraZeneca enters PD-1/VEGF space with $2B investment. - +5.0 AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
Reports AstraZeneca's equity investment in Summit; strategic oncology move. - +5.0 AstraZeneca takes a £1.5bn stake in US cancer drug developer as it steps up investment in America
Stake in US cancer developer, stepping up US investment. - +5.0 Physician Views Results: European pulmonologists see AstraZeneca's Trixeo as another option in asthma
Physicians see Trixeo as another asthma option. - +5.0 AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Strategic $2B equity investment in Summit. - +5.0 Astrazeneca invests $2B in Summit for bispecific/ADC combos
$2B investment in Summit for bispecific/ADC combinations. - +5.0 AstraZeneca bets $2 billion on Summit’s cancer drug in major ADC push
$2B bet on Summit drug as oncology push. - +4.2 AstraZeneca pours $2bn into Summit to advance cancer treatment
$2bn into Summit to advance cancer treatment. - +4.2 Key facts: Mid-Nov U.S. decision on ivonescimab; AstraZeneca (AZN) up
Upcoming US decision on ivonescimab; AstraZeneca shares up. - +4.2 Key facts: SMMT Seeks Financing; Shares Jump on AstraZeneca Pact
Summit pact with AstraZeneca reported; AstraZeneca a named party. - +4.2 Vital Signs: AstraZeneca's $2B seat at Summit's table
AstraZeneca takes $2B stake in Summit. - +4.2 Novo Nordisk and AstraZeneca Announce Licensing Deals Totaling $4.6 Billion
AstraZeneca licensing deal announced as part of $4.6B combined. - +4.2 Novo Nordisk Licenses Hengrui Pharma’s HRS-1596 and AstraZeneca Partners with Summit Therapeutics in $2 Billion Oncology Deal
AstraZeneca partners with Summit in $2B oncology deal. - −4.2 A $2 Billion Reason Why AstraZeneca Stock Is Down Today
Stock down on the day due to $2B deal. - −3.3 Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note
Shares fell more than the market. - +3.3 AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug
$2B bet on Summit cancer drug. - +3.3 Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
Analyst note on Summit after AstraZeneca deal; mildly supportive. - +3.3 AstraZeneca Backing Could Change The Case For Summit Therapeutics Stock
AstraZeneca backing seen as positive for Summit case. - +3.3 AstraZeneca Pays $2 Billion To Take On Pfizer, Merck, Bristol
Pays $2B to compete with big pharma rivals. - +3.3 Novo Nordisk and AstraZeneca Announce $4.6 Billion in Combined Pharmaceutical Licensing Deals
AstraZeneca licensing deal announced alongside Novo. - +3.3 Novo Nordisk and AstraZeneca Announce Licensing Deals with Hengrui Pharma and Summit Therapeutics
AstraZeneca licensing deal with Summit announced. - +3.3 SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet
AstraZeneca backs ivonescimab bet. - +3.3 Summit Therapeutics Rises as AstraZeneca Backs Ivonescimab With $2 Billion Investment
Summit rises on AstraZeneca's backing. - +3.3 Paolo Tarantino: AstraZeneca Repeats Its Asia-Developed Drug Bet
AstraZeneca repeats Asia-developed drug bet. - +3.3 Will AstraZeneca stock hold support as Summit Therapeutics partnership expands oncology pipeline?
Partnership expands oncology pipeline; share support questioned. - −3.3 Momentum Gains, AstraZeneca Stock Drops: Explained
AstraZeneca stock drops. - +2.5 SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare?
Focus on Summit, but AstraZeneca funding is the catalyst. - −1.7 AstraZeneca PLC (AZN) Stock Down 1.2% -- Now Undervalued? GF Sco
Shares down 1.2%, though framed as possibly undervalued. - −1.7 AstraZeneca stock after-hours at EUR 145.20: minus 0.65 percent
Shares slightly lower after hours. - −1.7 AstraZeneca stock after-hours at EUR 145.23: minus 0.63 percent versus prior close
Shares slightly lower after hours. - +0.8 FTSE 100 today: Stocks fall as shop prices slow; AstraZeneca buys Summit stake
FTSE report notes Summit stake amid falling market. - 0.0 AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating
Neutral rating reaffirmed by Deutsche Bank.
AstraZeneca: every day · Pharma and healthcare on 30 September 2026 · FTSE 100 overview for the day